EP2991627A4 - Composition de succédané de sang et procédé d'utilisation - Google Patents
Composition de succédané de sang et procédé d'utilisationInfo
- Publication number
- EP2991627A4 EP2991627A4 EP14791114.3A EP14791114A EP2991627A4 EP 2991627 A4 EP2991627 A4 EP 2991627A4 EP 14791114 A EP14791114 A EP 14791114A EP 2991627 A4 EP2991627 A4 EP 2991627A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- succanted
- blood
- composition
- succanted composition
- blood succanted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/41—Porphyrin- or corrin-ring-containing peptides
- A61K38/42—Haemoglobins; Myoglobins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Biophysics (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819426P | 2013-05-03 | 2013-05-03 | |
| PCT/US2014/036762 WO2014179793A1 (fr) | 2013-05-03 | 2014-05-05 | Composition de succédané de sang et procédé d'utilisation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP2991627A1 EP2991627A1 (fr) | 2016-03-09 |
| EP2991627A4 true EP2991627A4 (fr) | 2016-12-28 |
| EP2991627B1 EP2991627B1 (fr) | 2018-09-05 |
Family
ID=51844015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14791114.3A Active EP2991627B1 (fr) | 2013-05-03 | 2014-05-05 | Composition de succédané de sang et procédé d'utilisation |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9486508B2 (fr) |
| EP (1) | EP2991627B1 (fr) |
| JP (2) | JP6807740B2 (fr) |
| AU (1) | AU2014259617B2 (fr) |
| CA (1) | CA2910380C (fr) |
| ES (1) | ES2699579T3 (fr) |
| WO (1) | WO2014179793A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009049083A1 (fr) | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Particules d'imagerie |
| WO2009049089A1 (fr) | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Nanoparticules toroïdales dirigées ligand pour thérapie et imagerie de diagnostic |
| AU2010339809B2 (en) | 2009-12-17 | 2016-05-05 | The Washington University | Antithrombotic nanoparticle |
| JP2013527157A (ja) | 2010-04-15 | 2013-06-27 | ワシントン・ユニバーシティ | プロドラッグ組成物、プロドラッグナノ粒子およびその使用方法 |
| AU2014259617B2 (en) | 2013-05-03 | 2019-04-11 | Washington University | Blood substitute composition and method of use |
| CN105749257B (zh) * | 2016-01-25 | 2019-12-06 | 四川大学华西医院 | 一种血红蛋白类携氧纳米凝胶及其制备方法和用途 |
| GB201615050D0 (en) | 2016-09-05 | 2016-10-19 | Spheritech Ltd | Microparticles |
| JP7387597B2 (ja) | 2017-07-18 | 2023-11-28 | ヴァーテック・バイオ・インコーポレイテッド | ヘモグロビンを含む代用血液及び作製方法 |
| US12257289B2 (en) * | 2020-04-23 | 2025-03-25 | KaloCyte, Inc. | Self-assembling oxygen carrier compositions |
| AU2022232631A1 (en) * | 2021-03-11 | 2023-09-21 | KaloCyte, Inc. | Compositions and methods for removing bio-synthetic nano-particles from bodily fluids |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009049089A1 (fr) * | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Nanoparticules toroïdales dirigées ligand pour thérapie et imagerie de diagnostic |
| WO2011133635A2 (fr) * | 2010-04-20 | 2011-10-27 | Vindico NanoBio Technology Inc. | Nanoparticules biodégradables utilisées en tant que transporteurs d'oxygène inédits à base d'hémoglobine et procédés d'utilisation associés |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3925344A (en) | 1973-04-11 | 1975-12-09 | Community Blood Council | Plasma protein substitute |
| US4061736A (en) | 1975-02-02 | 1977-12-06 | Alza Corporation | Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin |
| US4473496A (en) | 1981-09-14 | 1984-09-25 | The United States Of America As Represented By The Secretary Of The Army | Intramolecularly crosslinked hemoglobin |
| US4529719A (en) | 1983-05-04 | 1985-07-16 | Tye Ross W | Modified crosslinked stroma-free tetrameric hemoglobin |
| US4600531A (en) | 1984-06-27 | 1986-07-15 | University Of Iowa Research Foundation | Production of alpha-alpha cross-linked hemoglobins in high yield |
| US4584130A (en) | 1985-03-29 | 1986-04-22 | University Of Maryland | Intramolecularly cross-linked hemoglobin and method of preparation |
| US4826811A (en) | 1986-06-20 | 1989-05-02 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| US5194590A (en) | 1986-06-20 | 1993-03-16 | Northfield Laboratories, Inc. | Acellular red blood cell substitute |
| GB8710598D0 (en) | 1987-05-05 | 1987-06-10 | Star Medical Diagnostics Ltd | Hemoglobin based blood substitute |
| GB8711614D0 (en) | 1987-05-16 | 1987-06-24 | Medical Res Council | Proteins |
| US5250665A (en) | 1991-05-31 | 1993-10-05 | The University Of Toronto Innovations Foundation | Specifically β-β cross-linked hemoglobins and method of preparation |
| JP2001348341A (ja) * | 2000-06-06 | 2001-12-18 | Terumo Corp | 低酸素状態の細胞および組織に有効な人工酸素運搬体 |
| WO2007123126A1 (fr) * | 2006-04-17 | 2007-11-01 | Juridical Foundation Osaka Industrial Promotion Organization | Agent PERMETTANT D'AMÉLIORER la TOLÉRANCE DIMINUÉE À l'exercice dans l'insuffisance cardiaque chronique |
| AU2014259617B2 (en) | 2013-05-03 | 2019-04-11 | Washington University | Blood substitute composition and method of use |
-
2014
- 2014-05-05 AU AU2014259617A patent/AU2014259617B2/en active Active
- 2014-05-05 ES ES14791114T patent/ES2699579T3/es active Active
- 2014-05-05 EP EP14791114.3A patent/EP2991627B1/fr active Active
- 2014-05-05 WO PCT/US2014/036762 patent/WO2014179793A1/fr not_active Ceased
- 2014-05-05 CA CA2910380A patent/CA2910380C/fr active Active
- 2014-05-05 JP JP2016512103A patent/JP6807740B2/ja active Active
-
2015
- 2015-11-02 US US14/930,396 patent/US9486508B2/en active Active
-
2016
- 2016-08-09 US US15/232,298 patent/US9655952B2/en active Active
-
2017
- 2017-03-16 US US15/460,843 patent/US9750241B2/en active Active
- 2017-08-15 US US15/677,826 patent/US20170367323A1/en not_active Abandoned
-
2019
- 2019-02-15 JP JP2019025379A patent/JP2019089832A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009049089A1 (fr) * | 2007-10-09 | 2009-04-16 | Washington University In St. Louis | Nanoparticules toroïdales dirigées ligand pour thérapie et imagerie de diagnostic |
| WO2011133635A2 (fr) * | 2010-04-20 | 2011-10-27 | Vindico NanoBio Technology Inc. | Nanoparticules biodégradables utilisées en tant que transporteurs d'oxygène inédits à base d'hémoglobine et procédés d'utilisation associés |
Non-Patent Citations (5)
| Title |
|---|
| ANDREA MOZZARELLI ET AL: "Haemoglobin-based oxygen carriers: research and reality towards an alternative to blood transfusions", BLOOD TRANSFUSION = TRASFUSIONE DEL SANGUE, 1 June 2010 (2010-06-01), Italy, pages s59 - s68, XP055319702, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897202/pdf/blt-08-s59.pdf> DOI: 10.2450/2010.010S * |
| CELIA BONAVENTURA ET AL: "Molecular Controls of the Oxygenation and Redox Reactions of Hemoglobin", ANTIOXIDANTS AND REDOX SIGNALING, vol. 18, no. 17, 21 January 2013 (2013-01-21), US, pages 2298 - 2313, XP055319711, ISSN: 1523-0864, DOI: 10.1089/ars.2012.4947 * |
| LAUREN GRAVITZ: "Artificial Red Blood Cells for Drug Delivery", 15 December 2009 (2009-12-15), XP055319647, Retrieved from the Internet <URL:https://www.technologyreview.com/s/416687/artificial-red-blood-cells-for-drug-delivery/> [retrieved on 20161115] * |
| See also references of WO2014179793A1 * |
| THOMAS M. S. CHANG: "From artificial red blood cells, oxygen carriers, and oxygen therapeutics to artificial cells, nanomedicine, and beyond", ARTIFICIAL CELLS, BLOOD SUBSTITUTES, AND IMMOBILIZATION BIOTECHNOLOGY., vol. 40, no. 3, 13 March 2012 (2012-03-13), US, pages 197 - 199, XP055319612, ISSN: 1073-1199, DOI: 10.3109/10731199.2012.662408 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019089832A (ja) | 2019-06-13 |
| ES2699579T3 (es) | 2019-02-11 |
| JP6807740B2 (ja) | 2021-01-06 |
| WO2014179793A1 (fr) | 2014-11-06 |
| US9750241B2 (en) | 2017-09-05 |
| AU2014259617B2 (en) | 2019-04-11 |
| CA2910380A1 (fr) | 2014-11-06 |
| US9486508B2 (en) | 2016-11-08 |
| US20170367323A1 (en) | 2017-12-28 |
| EP2991627A1 (fr) | 2016-03-09 |
| EP2991627B1 (fr) | 2018-09-05 |
| AU2014259617A1 (en) | 2015-11-12 |
| US20160051635A1 (en) | 2016-02-25 |
| US20170181424A1 (en) | 2017-06-29 |
| CA2910380C (fr) | 2020-09-29 |
| US9655952B2 (en) | 2017-05-23 |
| JP2016517892A (ja) | 2016-06-20 |
| US20160346358A1 (en) | 2016-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2999474A4 (fr) | Thérapeutique et procédé d'utilisation | |
| EP2895083A4 (fr) | Ligateur et procédé d'utilisation | |
| EP2991627A4 (fr) | Composition de succédané de sang et procédé d'utilisation | |
| EP2981222A4 (fr) | Système d'ablation médicale et procédé de fabrication | |
| EP2882365A4 (fr) | Cathéter d'ablation par micro-ondes et son procédé d'utilisation | |
| EP2967683A4 (fr) | Implant intervertébral adaptable et procédés d'utilisation | |
| EP3322358A4 (fr) | Instrument chirurgical et procédé d'utilisation | |
| EP2964115A4 (fr) | Elément de fixation osseuse et procédés d'utilisation | |
| EP2928539A4 (fr) | Fil-guide orientable et procédé d'utilisation | |
| EP2717787A4 (fr) | Clip endovasculaire avancé et procédé d'utilisation de celui-ci | |
| EP2872265A4 (fr) | Racleur de pipeline et son procédé d'utilisation | |
| EP2912178A4 (fr) | Super-activateurs et procédés d'utilisation de ceux-ci | |
| EP2964651A4 (fr) | Inhibiteurs de bmp et leurs procédés d'utilisation | |
| EP2983603A4 (fr) | Cathéters d'ablation cardiaque et leurs procédés d'utilisation | |
| EP2887930A4 (fr) | Composition anxiolytique, formulation et procédé d'utilisation | |
| EP2838633A4 (fr) | Composition démulsifiante et son procédé d'utilisation | |
| EP2837204A4 (fr) | Porte-joint extrudé et procédé d'utilisation | |
| EP2970311A4 (fr) | Inhibiteurs de bmp et leurs procédés d'utilisation | |
| EP2964235A4 (fr) | Compositions antimicrobiennes-antibiofilm et leurs procédés d'utilisation | |
| EP2968807A4 (fr) | Appareil respiratoire et son procédé d'utilisation | |
| EP2967397A4 (fr) | Association électro-chirurgicale d'outils et de procédés | |
| EP2983661A4 (fr) | Formulations d'oxabicycloheptanes et d'oxabicycloheptènes | |
| IL246269B (en) | Compositions and methods for treating fatty tissue buildup | |
| EP2945639A4 (fr) | Procédés de traitement d'états cardiaques | |
| DK3470018T3 (da) | Kryokonservering af levedygtige menneskehudssubstitutter |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20151202 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20161125 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/42 20060101ALI20161121BHEP Ipc: A61K 9/14 20060101AFI20161121BHEP Ipc: A61K 47/30 20060101ALI20161121BHEP Ipc: A61P 7/08 20060101ALI20161121BHEP Ipc: B82Y 5/00 20110101ALI20161121BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20170711 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/30 20060101ALI20180306BHEP Ipc: A61K 38/42 20060101ALI20180306BHEP Ipc: A61K 38/06 20060101ALI20180306BHEP Ipc: A61P 7/08 20060101ALI20180306BHEP Ipc: B82Y 5/00 20110101ALI20180306BHEP Ipc: A61K 9/14 20060101AFI20180306BHEP |
|
| INTG | Intention to grant announced |
Effective date: 20180322 |
|
| RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: WASHINGTON UNIVERSITY |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1037020 Country of ref document: AT Kind code of ref document: T Effective date: 20180915 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602014031888 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20180905 |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181206 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2699579 Country of ref document: ES Kind code of ref document: T3 Effective date: 20190211 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1037020 Country of ref document: AT Kind code of ref document: T Effective date: 20180905 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190105 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190105 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602014031888 Country of ref document: DE |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 |
|
| 26N | No opposition filed |
Effective date: 20190606 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190531 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190531 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20190531 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190505 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190505 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190531 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20140505 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20180905 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230607 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 602014031888 Country of ref document: DE Representative=s name: MAIWALD GMBH, DE |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20250521 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20250527 Year of fee payment: 12 Ref country code: ES Payment date: 20250627 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20250527 Year of fee payment: 12 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20250528 Year of fee payment: 12 |